ArticleOTO open
Histologic Origin and Survival in Salivary Duct Carcinoma: A Retrospective Cohort Study.
Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: To evaluate the impact of histologic origin on survival in salivary duct carcinoma (SDC) and characterize its clinical and pathologic features. Study Design: Retrospective cohort study. Setting: Single, tertiary academic medical center. Methods: This study included treatment-naïve patients diagnosed with SDC (2000-2024). Histologic origin (ex pleomorphic adenoma [PA] vs de novo) was determined pathologically or clinically. Kaplan-Meier analysis and log-rank tests assessed overall survival (OS) and disease-free survival (DFS). Cox regression estimated hazard ratios (HR) and 95% confidence intervals (CI) for 13 covariates. Results: Out of N = 85 SDC patients, 68 were treated with curative intent, including 43 de novo and 25 ex PA cases. Median follow-up was 19.8 months. OS and DFS survival were not significantly different by histologic origin (OS Conclusion: Histologic origin was not independently associated with OS or DFS, although numerically higher 2-year survival in SDC ex PA may suggest potential biologic differences between ex PA and de novo origins that warrant further study. Distant metastasis was the primary mechanism of treatment failure for both subtypes of SDC, highlighting the need to explore novel treatments, such as neoadjuvant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.